Histological or cytological confirmation of advanced malignancy ;
Progressive cancer at the time of study entry;
Adequate organ and marrow function as defined by the protocol;
Homologous recombination repair gene mutation.
You may not be if
Major surgery within 4 weeks of the first dose of study treatment.
Spinal cord compression or brain metastases unless asymptomatic, treated and stable and not requiring continuous corticosteroids at a dose of \>10mg prednisone/day or equivalent for at least 4 weeks prior to start of study treatment. Patients with leptomeningeal carcinomatosis are excluded.
Patients with myelodysplastic syndrome/acute myeloid leukaemia or with features suggestive of myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML).
Clareo Health | Phase I/II Clinical Study to Evaluate VB15010 Tablets in Patients With Advanced Solid Tumors
